SenesTech (SNES) delivered the revenue milestone it had already pre-announced, but the bottom line moved the wrong way. The rodent fertility-control company reported a third-quarter loss of $0.36 per share, missing the consensus estimate of a $0.31 loss by 16.1%. Earnings fell 28.6% year over year as the loss widened from $0.28 a year ago. Revenue of $1.1 million beat the $1.07 million consensus by 2.5% and grew 59.0% year over year. It was the company's first quarter above $1 million, but a preliminary figure of about $1.1 million had been released on October 15, so the top line held little surprise. That is the central tension. Commercial traction is real and broadening, yet the cost of buying that growth is still outrunning it, and the balance sheet is now part of the investment case.

The quality of the quarter deserves scrutiny. Revenue rose 42% sequentially, from $770,000 to $1.097 million, after a 56% jump the prior quarter. Sequential growth moderated in percentage terms even as the dollar increase grew. Gross profit hit a record $796,000. Gross margin of 72.6% slipped from 73.6% in Q2 but remained far above 62.8% a year ago. Operating expenses rose to $2.79 million from $1.78 million a year earlier. Sales and marketing spending more than doubled to $1.08 million, and G&A climbed to $1.29 million. GAAP net loss widened to $2.0 million from $1.8 million in Q2 and $1.3 million a year ago. Adjusted EBITDA loss was flat sequentially at $1.4 million. Operating cash burn improved for a third straight quarter, to $1.3 million from $1.7 million and $1.9 million. However, about $319,000 of the Q3 figure came from favorable working-capital changes rather than a structurally lower loss.

Beneath the headline, the business mix shifted further toward consumers. E-commerce revenue rose 52% sequentially and 337% year over year to about 71% of sales. On the call, management said Amazon revenue grew 76% quarter over quarter and Subscribe & Save subscribers jumped 161%. Combined subscribers rose 72%, and subscription revenue grew 53%. Evolve now accounts for 89% of product revenue at $979,000. Direct B2B, the piece management calls the next significant driver, grew 19% sequentially but only 2% year over year. That channel still has more promise than proof. Management's tone was noticeably more confident. Executives argued that e-commerce dilutes the usual fourth-quarter seasonality and that Amazon is not near saturation. They offered no formal guidance or breakeven target.

The catalyst list is longer than last quarter. It includes the following:

• Grove Collaborative as a new e-commerce channel.
• Sandstrom Partners engaged to sharpen branding and Amazon retention.
• Revenue-generating assessment services backed by AI analysis.
• A sales team expanding toward five reps by year end, plus a Pest World program launch.
• Municipal proof points: Chicago's Wicker Park Bucktown program cut average rat activity intensity 88% over 12 months, and Evolve now covers six Chicago-area districts.

Bears have legitimate ammunition, however. Cash fell to $4.0 million from $5.1 million in Q2 and $6.8 million in Q1. The earlier statement that runway extends into Q3 2027 was not repeated. After the quarter, the company raised $1.2 million through its at-the-market program. Call commentary put that at roughly 1.3 million shares sold below $1, implying roughly 20-25% dilution. Large holder Glenbrook has publicly criticized the dilution and the company's consumer pricing approach. Planned subscription pricing and packaging tests could pressure margins in the near term. The board is also discussing shifting compensation from cash to equity, which would conserve cash at the expense of further share issuance.

The market setup reflects that ambivalence. Investor sentiment remained positive but weakened meaningfully into the report, falling from 0.77 to 0.52. Shares sat at $1.14 heading into the release. That is 16.8% below the $1.37 open after the August report, which also marked the inter-earnings high, and 21.8% below the $1.46 200-day moving average. The stock touched a 52-week low of $0.55 on October 16, the day after the revenue pre-announcement, then more than doubled from that trough. Momentum and AVWAP trend readings are positive, while the price trend is neutral. That fits a stock that has rebounded sharply but has not reclaimed its longer-term trend.

The bottom line is that SenesTech's growth story got more credible this quarter. Record revenue, surging subscriptions and improving cash burn show the e-commerce engine is working. The financial model, however, did not improve at the same pace. Losses widened, the EPS estimate was missed, and the company is again funding operations by issuing stock at depressed prices. Until revenue growth visibly closes the gap with a $2.8 million quarterly expense base, dilution and runway will weigh as heavily on the shares as subscriber counts.